Astrocytic APOE4 genotype-mediated negative impacts on synaptic architecture in human pluripotent stem cell model
Stem Cell Reports · 2023
DOI: 10.1016/j.stemcr.2023.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Reports, 2023. Verfasst von Hirotaka Watanabe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: hwatanabe@keio.jp. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Pluripotent Stem Cells. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Keio University, School of Medicine, Keio University, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The APOE4 genotype is the strongest risk factor for the pathogenesis of sporadic Alzheimer's disease (AD), but the detailed molecular mechanism of APOE4-mediated synaptic impairment remains to be determined. In this study, we generated a human astrocyte model carrying the APOE3 or APOE4 genotype using human induced pluripotent stem cells (iPSCs) in which isogenic APOE4 iPSCs were genome edited from healthy control APOE3 iPSCs. Next, we demonstrated that the astrocytic APOE4 genotype negatively affects dendritic spine dynamics in a co-culture system with primary neurons. Transcriptome analysis revealed an increase of EDIL3, an extracellular matrix glycoprotein, in human APOE4 astrocytes, which could underlie dendritic spine reduction in neuronal cultures. Accordingly, postmortem AD brains carrying the APOE4 allele have elevated levels of EDIL3 protein deposits within amyloid plaques. Together, these results demonstrate the novel deleterious effect of human APOE4 astrocytes on synaptic architecture and may help to elucidate the mechanism of APOE4-linked AD pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: hwatanabe@keio.jp.
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Research Fellow of Japan Society for the Promotion of Science (JSPS), Tokyo 102-0083, Japan.
- Center for Integrated Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan; Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurolo…
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
Förderung
- Keio University
- School of Medicine, Keio University
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Watanabe, H., Murakami, R., Tsumagari, K., Morimoto, S., Hashimoto, T., Imaizumi, K., Sonn, I., Yamada, K., Saito, Y., Murayama, S., Iwatsubo, T., & Okano, H. (2023). Astrocytic APOE4 genotype-mediated negative impacts on synaptic architecture in human pluripotent stem cell model. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2023.08.002
Vancouver
Watanabe H, Murakami R, Tsumagari K, Morimoto S, Hashimoto T, Imaizumi K, et al. Astrocytic APOE4 genotype-mediated negative impacts on synaptic architecture in human pluripotent stem cell model. Stem Cell Reports. 2023. doi:10.1016/j.stemcr.2023.08.002
BibTeX
@article{Watanabe2023,
author = {Watanabe, Hirotaka and Murakami, Rei and Tsumagari, Kazuya and Morimoto, Satoru and Hashimoto, Tadafumi and Imaizumi, Kent and Sonn, Iki and Yamada, Kaoru and Saito, Yuko and Murayama, Shigeo and Iwatsubo, Takeshi and Okano, Hideyuki},
title = {Astrocytic APOE4 genotype-mediated negative impacts on synaptic architecture in human pluripotent stem cell model},
journal = {Stem Cell Reports},
year = {2023},
doi = {10.1016/j.stemcr.2023.08.002}
}
EUVIMED